Advancing Manufacture of Cell and Gene Therapies IX
Preliminary Program
Plenary Speaker
Denis Claude Roy, Ph.D.
Professor, Faculty of Medicine
Université de Montréal
"Advanced therapeutics biomanufacturing in the academic-hospital setting and patient impact"
Keynote Speakers
Susan Abu-Absi, Ph.D
Chief Operating Officer
Be Bio
"Engineering the Future of CGT Manufacturing: Insights from Clinical Development and Commercialization of Advanced Therapies for Oncology and Rare Disease"
Richard D. Braatz, Ph.D.
Edwin R. Gilliland Professor of Chemical Engineering
Director, Center for Continuous mRNA Manufacturing
MIT
"Intensification of Cell and Gene Therapy Manufacturing: Modeling, Design, and Control"
Chris Stevens
Chief Operating Officer
Rocket Pharma
"From Rare Diseases to Common Conditions: Advancing Cell & Gene Therapy for the Next Era of Medicine"
Invited Speakers
Stephen Balakirsky, Georgia Institute of Technology, (United States)
Neil Blackburn, Omniabio, (United States)
Colin Cook, Xdemics Corporation, (United States)
Lindsay Fraser, Cytomos, (United Kingdom)
Alois Jungbauer, BOKU University, (Austria)
Amine A. Kamen, McGill University , (Canada)
Lise Munsie, BlueRock Therapeutics, (United States)
Ioannis Papantoniou, KU Leuven, (Belgium)
Rodney L. Rietze, Ph.D., Streamline Bio, (USA)
Antonio Roldao, iBET (Portugal)
Kris Saha, University of Wisconsin, (United States)
Luis Santos, Prime Medicine, (USA)
Margarida Serra, IBET, (Portugal)
Dan Strange, Cellular Origins, (United Kingdom)
John Tomishen, Cellares, (United States)
Tracey Turner, Bristol Myers Squibb, (United States)
Stephen Ward, Cell Therapy Catapult, (United Kingdom)
Workshop Description
Improving Cost-Effectiveness and Patient Access for Cell and Gene Therapies
Chairs
Suzanne Farid, University College London (UCL), UK
Patrícia Gomes-Alves, iBET, Portugal
Fabien Moncaubeig, Treefrog Therapeutics, France
This workshop will explore the critical intersection of manufacturing innovation, cost-effectiveness, and patient access in the development and delivery of cell and gene therapies (CGTs). While these therapies offer transformative potential for a wide range of diseases, high production costs, complex supply chains, and reimbursement challenges continue to limit their reach.
The session will focus on how process improvements and early-stage process economics analysis can help reduce the cost of goods (COG), improve scalability, and support the broader availability of CGTs. Through a combination of hands-on interactive case studies, roundtable discussions and expert talks, we will tackle:
- Barriers to global patient access
- Cost of goods analysis and process change economics
- Strategies for cost-effective commercialization of CGTs
A key feature of the workshop will be a hands-on case study using a web-based economics tool, where participants will evaluate scale-out versus scale-up manufacturing strategies for viral vector-based gene therapies. This interactive exercise will guide attendees through analysis of upstream and downstream options and their impact on cost of goods, development costs, and overall commercial viability.
Attendees will have the opportunity to engage with colleagues and experts developing advanced therapies and contribute to shaping practical, cost-conscious strategies for the future of CGTs.
Abstract Submissions
Abstract Submissions are closed. Abstracts for all presentations will be made available to conference participants prior to the start of the conference.
Click here to see the status of your abstract.
Poster Guidelines
The best posters display a succinct statement of major conclusions at the beginning, followed by supporting text in later segments and a brief summary at the end. Click here for instructions and more information.
Poster Size: 1.0 meter wide and 1.5 meters in length (Portrait style).